Search

everythinglearnresearchcommunity

for

Search:↓

New pyrazole-based inhibitors show promise for treating metabolic diseases and other conditions.

Ritlecitinib successfully treated a child's alopecia universalis after baricitinib failed.

Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.

RU58841, a substance from France, can potentially block the effects of hormones that cause hair loss and excessive hair growth, performing better than a similar substance, cyproterone acetate.

Early use of infliximab in severe pediatric Crohn's disease can lead to significant improvement and remission.

Cepharanthine analogues, especially tetrandrine, show potential for treating COVID-19.

RTA 408 cream protects mice from radiation skin damage.

Systemic retinoids do not increase COVID-19 risk or severity.

Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.

Cytarabine can cause multiple organ toxicities, especially neurotoxicity, but better research methods are needed to fully understand and predict these effects.

ATR12-351 ointment safely delivers LEKTI protein to the skin, reducing enzyme activity in Netherton syndrome.

CRH promotes fat production in skin cells, affecting conditions like acne.

The rs1128977 gene variant may affect cholesterol and body measurements.

Cyproterone acetate and ethinylestradiol effectively reduce hirsutism and acne in women.

Ruxolitinib cream effectively targets and treats inflammatory skin diseases.

Low-dose Ritlecitinib may help children with stubborn Alopecia Areata.

High-dose intravenous iron therapy doesn't interfere with treatment improvements in IBD patients with iron deficiency anemia.

Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.

Orlistat might block the body's ability to absorb thyroid medication.

Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.

Blocking the enzyme 11β-HSD1 might help treat obesity and metabolic issues.

In 2002, various drugs caused serious side effects, including vitamin B12 deficiency, heart issues, blindness, hypersexuality, allergic reactions, blood clotting problems, pupil dilation, capillary leak syndrome, muscle breakdown, hepatitis, skin reactions, and lupus.

Pexidartinib often causes liver issues and fatigue, especially in women.

Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.

Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.

Targeted protein degraders show promise in treating cancer but need to target more diverse proteins.

Thyrotropin-releasing hormone may help control skin and hair growth and could aid in treating related disorders.

Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

Second-generation antipsychotics offer no significant benefit over first-generation ones for schizophrenia.